Analyst Price Targets — PLRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 3, 2025 7:24 pm | — | Stifel Nicolaus | $3.00 | $1.38 | TheFly | Pliant Therapeutics downgraded to Hold from Buy at Stifel |
| March 3, 2025 5:25 pm | — | Leerink Partners | $2.00 | $1.38 | TheFly | Pliant Therapeutics downgraded to Market Perform from Outperform at Leerink |
| September 13, 2024 6:43 am | Ed Arce | H.C. Wainwright | $38.00 | $11.84 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Pliant Therapeutics (PLRX) |
| September 9, 2024 6:28 am | Faisal Khurshid | Leerink Partners | $33.00 | $12.87 | TheFly | Pliant Therapeutics assumed with an Outperform at Leerink |
| May 23, 2024 8:44 am | Yasmeen Rahimi | Piper Sandler | $40.00 | $13.85 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Pliant Therapeutics (PLRX) |
| May 7, 2024 8:29 am | Alex Thompson | Stifel Nicolaus | $32.00 | $13.91 | StreetInsider | Pliant Therapeutics (PLRX) PT Lowered to $32 at Stifel |
| May 7, 2024 7:42 am | Jeff Jones | Oppenheimer | $48.00 | $13.79 | StreetInsider | Pliant Therapeutics (PLRX) PT Raised to $48 at Oppenheimer |
| May 7, 2024 7:09 am | Ed Arce | H.C. Wainwright | $36.00 | $13.79 | StreetInsider | Pliant Therapeutics (PLRX) PT Lowered to $36 at H.C. Wainwright |
| May 7, 2024 6:19 am | Brian Abrahams | RBC Capital | $45.00 | $13.79 | StreetInsider | Pliant Therapeutics (PLRX) PT Lowered to $45 at RBC Capital |
| December 7, 2022 7:12 am | — | J.P. Morgan | $42.00 | $17.18 | Benzinga | JP Morgan Initiates Coverage On Pliant Therapeutics with Overweight Rating, Announces Price Target of $42 |
Latest News for PLRX
Pliant Therapeutics trades at a deep discount to net cash after Bexotegrast's Phase 3 failure, with a $70M market cap versus $186M cash. Activist Kevin Tang holds 9.6%; given the 85%+ institutional base, the March 2026 poison pill expiration signals a potential liquidation or premium buyout. PLRX's cash burn has been slashed, extending runway to 2028, but continued independent operation is untenable; forced…
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference being held in a virtual format February 25-26, 2026.
Pliant Therapeutics, Inc. (NASDAQ: PLRX - Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totaling 3,750,180 shares, an increase of 21.0% from the December 31st total of 3,100,213 shares. Based on an average daily trading volume, of 1,077,903
Pliant Therapeutics, Inc. (NASDAQ: PLRX) is capturing attention with promising trial results for its cancer therapy, despite a sharp stock decline.
One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable ongoing responses with median time on treatment of 15 months Company to accelerate development of PLN-101095 with initiation of a Phase 1b expansion trial in 2026 Strong cash position supports planned operations through 2028 SOUTH SAN FRANCISCO, Calif., Dec. 04,…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PLRX.
U.S. House Trading
No House trades found for PLRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.